Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders

CNS Drugs

Volumn 5, Issue 3, 1996, Pages 200-223

  Bertilsson, Leif ^a   Dahl, Marja Liisa ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DIAZEPAM; IMIPRAMINE; MEPHENYTOIN; OMEPRAZOLE; SPARTEINE;

DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029979414     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605030-00006     Document Type: Review

References (152)

1. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment wich imipramine-like compounds. Life Sci 1967; 6: 1895-903
2. Dahl SG. Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 1986; 11: 36-61
3. Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc., 1992
4. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346-52
5. Mahgoub A, Idle JR, Dring DG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-6
6. Tucker GT, Silas JH, Iyun AO, et al. Polymorphic hydroxylation of debrisoquine in man [letter]. Lancet 1977; 2: 718
7. Eichelbaum M, Spannbrucker N, Steinke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-7
8. Eichelbaum M, Bertilsson L, Säwe J, et al. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31: 184-6
9. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992: 657-85
10. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-5
11. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-52
12. Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17: 102-5
13. Alván G, Bechtel P, Iselius L, et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7
14. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97
15. Masimirembwa CM. Pharmacogenetics of drug metabolising enzymes in a black African population [thesis]. Stockholm: Karolinska Institute, 1995
16. Masimirembwa C, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 37: 656-61
17. Gonzalez FJ, Matsunaga T, Nagata K, et al. Debrisoquine 4-hydroxylase: characterization of anew P450 gene family, regulation, chromosomal mapping and molecular analysis of the DA rat polymorphism. DNA 1987; 6: 149-61
18. Zanger UM, Vilbois F, Hardwick JP, et al. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447-54
19. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolisers of debrisoquine. J Biol Chem 1990; 265: 17209-14
20. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-32
21. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990; 347: 773-6
22. Gaedigk A, Blum M, Gaedigk R, et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48: 943-50
23. Broly F, Gaedigk A, Heim M, et al. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-58
24. Dahl M-L, Johansson I, Porsmyr Palmertz M, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12-7
25. Johansson I, Oscarsson M, Yue QY, et al. Genetic analysis of the Chinese CYP2D6 locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-9
26. Masimirembwa CM, Johansson I, Hasler JA, et al. Genetic polymorphism of cytochrome P450 2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-80
27. Evans WE, Relling MV, Rahman A, et al. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91: 2150-4
28. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9
29. Bertilsson L, Dahl M-L, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation: implication for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Brussels: European Commission, 1995: 85-136
30. Tyndale R, Aoyama T, Broly F, et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1: 26-32
31. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993; 3: 123-30
32. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63
33. Dahl M-L, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-20
34. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenyloin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-8
35. Sohn D-R, Shin S-G, Park C-W, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504-7
36. Johansson I, Yue QY, Dahl M-L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40: 553-6
37. Yokota H, Tamura S, Furuya H, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vitro rates of sparteine metabolism. Pharmacogenetics 1993; 3: 256-63
38. Dahl M-L, Yue Q-Y, Roh H-K, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5: 159-64
39. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102-7
40. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22
41. Nei M, Saitou N. Genetic relationship of human populations and ethnic differences in reactions to drugs and food. In: Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R Liss, 1986: 21-37
42. de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8
43. Chang M, Duhl M-L, Tybring G, et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians. Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-63
44. Wedlund PJ, Aslanian WS, McAllister CB, et al. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-80
45. Sanz EJ, Villen T, Alm C, et al. S-mephenytoin hydroxylation phenotype in a Swedish population determined after co-administration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-9
46. Jurima M, Inaba T, Kadar D, et al. Genetic polymorphism of mephenyloin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483-7
47. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207
48. Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160-9
49. Skjelbo E, Brøsen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylalion of imipramine. Clin Pharmacol Ther 1991; 49: 18-23
50. Ward SA, Helsby NA, Skjelbo E, et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31: 689-92
51. Rudorfer MV, Potter WZ. Pharmacokinetics of antidepressants. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1353-63
52. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28: 26-40
53. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriplyline in twins: influence of genetic factors and drug therapy. BMJ 1969; 2: 764-8
54. Åsberg M, Evans DAP, Sjöqvist F. Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet 1971; 8: 129-35
55. Hammer W, Mårtens S, Sjöqvist F. Comparative studies of the metabolism of desmethylimipramine, nortriptyline and oxphenylbutazone in man. Clin Pharmacol Ther 1969; 10: 44-6
56. Alexanderson B. Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and oral doses - a crossover study. Eur J Clin Pharmacol 1972; 5: 7-10
57. Mellström B, Bertilsson L, Träskman L, et al. Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology 1979; 19: 282-7
58. Alexanderson B, Borgå O. Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 1973; 5: 174-80
59. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972: 4: 201-5
60. Bertilsson L, Eichelbaum M, Mellström B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673-7
61. Mellström B, Bertilsson L, Säwe J, et al. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189-93
62. Mellström B, Bertilsson L, Birgersson C, et al. E- and Z-10-hydroxylation of nortriptyline by human liver microsomes - methods and characterisation. Drug Metab Disp 1983; 11: 115-9
63. Nordin C, Siwers B, Benitez J, et al. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients - relationship to the debrisoquine metabolic ratio. Br J Clin Pharmacol 1985; 19: 832-5
64. Gram LF, Brøsen K, Kragh-Sørensen P, et al. Steady state plasma levels of E- and Z-10-OH-nortriptyline in nortriplyline treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11: 508-14
65. Nordin C, Bertilsson L, Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxy-nortriptyline. Clin Pharmacol Ther 1987; 42: 10-9
66. Potter WZ, Bertilsson L, Sjöqvist F. Clinical pharmacokinetics of psychotropic drugs - fundamental and practical aspects. In: van Praag HM, Lader MH, Rafaelson OJ, et al., editors. Handbook of biological psychiatry: part VI. New York: Marcel Dekker Inc., 1981: 71-134
67. Bertilsson L, Åberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15: 388-90
68. Spina E, Birgersson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microxomes. Clin Pharmacol Ther 1984; 36: 677-82
69. Spina E, Steiner E, Ericsson O, et al. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1987; 41: 314-9
70. Dahl M-L, Iselius L, Alm C, et al. Polymorphic 2-hydroxylation of desipramine: a population and family study. Eur J Clin Pharmacol 1993; 44: 445-50
71. Balant-Gorgia AE, Schultz P, Dayer P, et al. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 1982; 232: 215-22
72. Balant-Gorgia AE, Balant LP, Genet Ch, et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986; 31: 449-55
73. Mellström B, Bertilsson L, Lou Y-C, et al. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1983; 34: 516-20
74. Mellström B, Säwe J, Bertilsson L, et al. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986; 39: 369-71
75. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 1994; 31: 177-86
76. Dahl M-L, Tybring G, Elwin C-E, et al. Stereoselective disposition of mianserin is related to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther 1994; 56: 176-83
77. Firkusny L, Gleiter H. Maprotiline metabolism appears to cosegregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994; 37: 383-8
78. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-87
79. Sindrup SH, Brøsen K, Hansen MGJ, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-7
80. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 1993; 71: 1002-9
81. Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-7
82. Sellers EM, Ball SE, Cheung SW, et al. Inhibition by venlafaxine (VF) and other 5HT uptake inhibitors of the polymorphic-enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharmacology; 1993 Dec 13-17; Honolulu, 163
83. Gram LF. Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 1977; 2: 237-51
84. Preskorn SH, Dorey RC, Jerkovich GS. Therapeutic drug monitoring of tricyclic antidepressants. Clin Chem 1988; 34: 822-8
85. Åsberg M, Cronholm B, Sjöqvist F, et al. Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 3: 331-4
86. Bertilsson L, Mellström B, Sjöqvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implication. Lancet 1981; 1: 560-1
87. Sjöqvist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: pharmacogenetics. In: Usdin E, Åsberg M, Bertilsson L, et al., editors. Frontiers in biochemical and pharmacological research in depression. New York: Raven Press, 1984: 359-72
88. Sjöqvist F, Bertilsson L. Slow hydroxylation of tricyclic antidepressants - relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reactions to drugs and xenobiotics. New York: Alan R Liss Inc., 1986: 169-88
89. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit 1989; 11: 415-20
90. Brøsen K, Klysner R, Gram LF, et al. Steady-stale levels of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679-84
91. Bertilsson L, Åberg-Wistedl A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478-80
92. Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17: 433-40
93. Chan K, Chiun H, Lee S, et al. Estimating plasma concentrations of desipramine in Chinese depressed patients using the repeated one-point method. Br J Clin Pharmacol 1988; 26: 638-9P
94. Lin KM, Poland RE, Smith MW, et al. Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull 1991; 27: 427-39
95. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537-47
96. Cooke RG, Warsh JJ, Stancer HC, et al. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin Pharmacol Ther 1984; 36: 343-9
97. Brøsen K, Gram LF, Klysner R, et al. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986; 30: 43-9
98. Sindrup SH, Brøsen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit 1990; 12: 445-9
99. Brøsen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988; 43: 400-6
100. von Bahr C, Spina E, Birgersson C, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985; 34: 2501-5
101. Hirschowitz J, Bennet JA, Zemlan FP, et al.Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol 1983; 3: 376-9
102. Inaba T, Jurima M, Mahon WA, et al. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13: 443-8
103. Gram LF, Fredricson-Overø K. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. BMJ 1972; 1: 463-5
104. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 13: 57-67
105. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1-12
106. Crewe HR, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
107. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-4
108. Bertschy G, Vandel S, Vandel R, et al. Fluvoxamine tricyclic antidepressant interaction: an accidental finding. Eur J Clin Pharmacol 1991; 40: 119-20
109. Spina E, Campo GM, Avenso A, et al. Interaction between fluvoxamine und imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194-6
110. Spina E, Pollicino AM, Avenso A, et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-6
111. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
112. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3: 61-70
113. Syvälahti EKG, Lindberg R, Kallio J, et al. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986; 22: 89-92
114. Dahl-Puustinen M-L, Lidén A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81
115. Dahl M-L, Ekqvist B, Widén J, et al. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99-102
116. Froemming JS, Francis Lam YW, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17: 396-423
117. Chakraborty BS, Hubbard JW, Hawes EM, et al. Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 1989; 37: 45-8
118. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31: 655-60
119. LLerena A, Alm C, Dahl M-L, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92-7
120. LLerena A, Dahl M-L, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14: 261-4
121. 2 Dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-8
122. Potkin SG, Shen Y, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12: 167-72
123. Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195-201
124. Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140: 490-1
125. Wood AJJ, Zhou H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350-73
126. Baldessarini RJ, Frankenburg ER. Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324: 746-54
127. Dahl M-L, LLerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-4
128. Fischer B, Vogels G, Maurer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal recombinant cytochrome P4502D6. J Pharmacol Exp Ther 1992; 260: 1355-60
129. Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74
130. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1943; 53: 503-14
131. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994; 55: 293-304
132. Bertilsson L, Carrillo JA, Dahl M-L, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-3
133. Haring C, Meise U, Humpel C, et al. Dose related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacol 1989; 99: 538-40
134. Vainer JL, Chouinard G. Interaction between caifeine and clozapine. J Clin Psychopharmacol 1994; 14: 284-5
135. Carrillo JA, Jerling M, Bertilsson L. Comments to 'Interaction between caffeine and clozapine'. J Clin Psychopharmacol 1995; 15: 376-7
136. von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234-40
137. 2-receptor antagonist - covaries with the ability to hydroxylate debrisoquine. 34th Nordic Meeting of Pharmacology, Toxicology and Clinical Pharmacology; 1989 Jun 26-28; Reykjavik
138. Huang M-L, van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-68
139. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450 bufI.P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987; 148: 1144-50
140. Niznik HB, Tyndale RF, Sallee RF, et al. The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H] GBR-12935 binding proteins. Arch Biochem Biophys 1990; 276: 424-32
141. Kalow W, Tyndale RF. Debrisoquine/sparteine monooxygenase and other P450s in brain. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, Inc., 1992: 649-56
142. Bertilsson L, Alm C, de las Carreras C, et al. Debrisoquine hydroxylation polymorphism and personality [letter]. Lancet 1989; 1: 555
143. LLerena A, Edman G, Cobaleda J, et al. Relationship between personality and debrisoquine hydroxylation capacity - suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23-8
144. Brøsen K, Sindrup SH, Skjelbo E, et al. Role of genetic polymorphism in psychopharmacology - an update. In: Gram LF, Balant LP, Meltzer HY, et al., editors. Clinical pharmacology in psychiatry. Berlin, Heidelberg: Springer Verlag, 1993: 199-211
145. Bertilsson L, Henthorn TK, Santz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-55
146. Zhang Y, Reviriego J, Lou YQ, et al. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990; 48: 496-502
147. Bertilsson L, Kalow W. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations, but not in Chinese populations? Clin Pharmacol Ther 1993; 53: 608-10
148. Kalow W, Bertilsson L. Interethnic factors affecting drug activity. In: Testa B, Meyer UA, editors. Advances in drug research. Vol. 25. London: Academic Press, 1994: 1-53
149. Ghoneim MM, Korttila K, Chiang CK, et al. Diazepam effect and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981; 29: 749-56
150. Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987; 32: 211-5
151. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-7
152. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471-6